Chronic lymphocytic leukemia with MDM2 amplification as an alternative pathway to TP53 dysfunction

被引：0
|
作者：
Hunter, Sally [1 ,6 ]
Ryland, Georgina [1 ,2 ,6 ]
Pang, Jia-Min [1 ,6 ]
Ninkovic, Slavisa [3 ]
Dun, Karen [3 ,4 ]
Seymour, John F. [5 ,7 ]
Blombery, Piers [1 ,2 ,5 ,6 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Australia
[3] St Vincents Hosp Melbourne, Victorian Canc Cytogenet Serv, Melbourne, Vic, Australia
[4] St Vincents Hosp Melbourne, Dept Haematol, Melbourne, Vic, Australia
[5] Peter MacCallum Canc Ctr, Clin Haematol, Melbourne, Vic, Australia
[6] Royal Melbourne Hosp, Melbourne, Vic, Australia
[7] Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia
来源：
LEUKEMIA & LYMPHOMA | 2024年 / 65卷 / 14期
关键词：
D O I：
10.1080/10428194.2024.2398659
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2215 / 2218
页数：4
相关论文
共 50 条
  • [21] Selection of new TP53 mutations by therapy in chronic lymphocytic leukemia
    Trbusek, Martin
    Malcikova, Jitka
    Mayer, Jiri
    LEUKEMIA RESEARCH, 2011, 35 (07) : 981 - 982
  • [22] ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
    S Pospisilova
    D Gonzalez
    J Malcikova
    M Trbusek
    D Rossi
    A P Kater
    F Cymbalista
    B Eichhorst
    M Hallek
    H Döhner
    P Hillmen
    M van Oers
    J Gribben
    P Ghia
    E Montserrat
    S Stilgenbauer
    T Zenz
    Leukemia, 2012, 26 : 1458 - 1461
  • [23] ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
    Pospisilova, S.
    Gonzalez, D.
    Malcikova, J.
    Trbusek, M.
    Rossi, D.
    Kater, A. P.
    Cymbalista, F.
    Eichhorst, B.
    Hallek, M.
    Doehner, H.
    Hillmen, P.
    van Oers, M.
    Gribben, J.
    Ghia, P.
    Montserrat, E.
    Stilgenbauer, S.
    Zenz, T.
    LEUKEMIA, 2012, 26 (07) : 1458 - 1461
  • [24] TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia
    Zainuddin, Norafiza
    Murray, Fiona
    Kanduri, Meena
    Gunnarsson, Rebeqa
    Smedby, Karin E.
    Enblad, Gunilla
    Jurlander, Jesper
    Juliusson, Gunnar
    Rosenquist, Richard
    LEUKEMIA RESEARCH, 2011, 35 (02) : 272 - 274
  • [25] TP53 mutations and MDM2 gene amplification in squamous-cell carcinomas of the esophagus in South Thailand
    Tanière, P
    Martel-Planche, G
    Puttawibul, P
    Casson, A
    Montesano, R
    Chanvitan, A
    Hainaut, P
    INTERNATIONAL JOURNAL OF CANCER, 2000, 88 (02) : 223 - 227
  • [26] Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas
    Galic, Vijaya
    Willner, Julia
    Wollan, Melissa
    Garg, Ruchi
    Garcia, Rochelle
    Goff, Barbara A.
    Gray, Heidi J.
    Swisher, Elizabeth M.
    GENES CHROMOSOMES & CANCER, 2007, 46 (03): : 239 - 247
  • [27] Development of chronic myelogenous leukemia in a case of chronic lymphocytic leukemia with Tp53 gene deletion
    Gupta, A.
    Parihar, M.
    Yadav, A. K.
    Chakrapani, A.
    JOURNAL OF POSTGRADUATE MEDICINE, 2015, 61 (02) : 137 - +
  • [28] Genetic evaluation in TP53 and MDM2 as modifier genes for congenital aniridia
    Fernandes-Lima, Zuleide Silva
    Fraga, Lucas Rosa
    Wachholz, Gabriela Elis
    Schuler-Faccini, Lavinia
    Boquett, Juliano Andre
    GENE REPORTS, 2018, 13 : 235 - 236
  • [29] TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women
    Zajac, Agnieszka
    Smolarz, Beata
    Stachowiak, Grzegorz
    Wilczynski, Jacek R.
    MEDICAL ONCOLOGY, 2014, 31 (11) : 1 - 6
  • [30] TP53, MDM2, NQO1, and Susceptibility to Cervical Cancer
    Hu, Xiaoxia
    Zhang, Zhengyan
    Ma, Duanduan
    Huettner, Phyllis C.
    Massad, L. Stewart
    Nguyen, Loan
    Borecki, Ingrid
    Rader, Janet S.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (03) : 755 - 761
12345